Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for Targeted Drug Delivery to Nonsmall Cell Lung Cancer" (2015)
Total Page:16
File Type:pdf, Size:1020Kb
University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 5-2015 Design, Development and Evaluation of Erlotinib- Loaded Hybrid Nanoparticles for Targeted Drug Delivery to NonSmall Cell Lung Cancer Bivash Mandal University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Pharmaceutics and Drug Design Commons Recommended Citation Mandal, Bivash , "Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for Targeted Drug Delivery to NonSmall Cell Lung Cancer" (2015). Theses and Dissertations (ETD). Paper 166. http://dx.doi.org/10.21007/etd.cghs.2015.0196. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for Targeted Drug Delivery to NonSmall Cell Lung Cancer Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Pharmaceutical Sciences Research Advisor George C. Wood, Ph.D. Committee Himanshu Bhattacharjee, Ph.D. James R. Johnson, Ph.D. Timothy D. Mandrell, Ph.D. Duane D. Miller, Ph.D. DOI 10.21007/etd.cghs.2015.0196 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/166 Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for Targeted Drug Delivery to Non-Small Cell Lung Cancer A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Bivash Mandal May 2015 Portions of Chapter 1 © 2013 by Elsevier. All other material © 2015 by Bivash Mandal. All rights reserved. ii DEDICATION This dissertation is dedicated to my parents, Mr. Puspendu Mandal and Mrs. Rina Mandal and my beloved wife Chandrima Sinha for their unconditional love, care and constant encouragement to succeed. iii ACKNOWLEDGEMENTS I am truly grateful and thankful to my mentor Dr. George Wood for the opportunities, support, motivation and guidance to conduct my doctoral research in his laboratory at the Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center (UTHSC). Dr. Wood is a wonderful mentor and person. The graduate education, research and training in Dr. Wood’s lab were a valuable learning experience. I believe this experience would help me in my future career. I would like to express sincere thanks to my dissertation committee members, Drs. James R. Johnson, Duane D. Miller, Timothy D. Mandrell, and Himanshu Bhattacharjee for their valuable suggestions and direction for my dissertation project. I am immensely thankful to Plough Center for Sterile Drug Delivery Systems, (formerly known as Parenteral Medications Laboratories), UTHSC for funding my research. I thank Dr. Laura A. Thoma, Dr. Robert J. Nolly, Mr. Frank Horton, and Ms. Gwen Stornes for their help and assistance. Support from my lab members Dr. Nivesh Mittal and Mr. Pavan Balabathula has been invaluable and critical to my dissertation research. I extend my gratitude to Dr. Subhash Chauhan and his group for their guidance and help in cell-based assays and biochemical techniques. My special thanks should also go to Dr. A.P. Naren and his group for their assistance at various stages of the project. I welcome this opportunity to acknowledge Dr. Amanda Preston, Mr. Brian R. Morrow, Ms. Michelle Sims, and Dr. Yunming Hu for their help with TEM, SEM and confocal microscopy. Finally, I express my sincere gratitude and thank to my parents Mr. Puspendu Mandal and Mrs. Rina Mandal for their love and care. I would like to convey my heartiest congratulations to my beloved wife Dr. Chandrima Sinha for her love, understanding and constant encouragement. I am grateful to my lovely sisters Mrs. Mallika Das and Mrs. Sulekha Kayal, brother-in-laws Mr. Biswajit Das and Mr. Bikram Kayal, nephew Satyam Das and niece Sradha Kayal for their endless love and support. iv ABSTRACT The objective of this work was to design, develop and evaluate erlotinib-loaded core-shell type lipid albumin hybrid nanoparticles (CSLAHNPs) for targeted drug delivery to non-small cell lung cancer (NSCLC). Erlotinib (ETB) is a highly selective, potent and reversible inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR) which is overexpressed (50-90%) in NSCLC. ETB is marketed as film coated tablets for oral delivery. However, poor survival rate along with life-threatening adverse effects were reported from oral administration. Nanoparticulate delivery system of ETB might be advantageous to target the tumor cells, thereby increasing therapeutic efficacy and reducing off-targeting toxicities of ETB to healthy cells. In this work, a unique nanoparticulate carrier termed as CSLAHNPs was used for targeted delivery of ETB. The CSLAHNPs system was composed of albumin core and phospholipid bilayer shell. For active targeting to EGFR positive NSCLC, anti-EGFR half-antibodes (hAbs) were conjugate to EGFR expressing NSCLC. Overall hypothesis was to improve the efficacy of ETB in EGFR positive NSCLC using the targeted hAb-ETB- CSLAHNPs and untargeted ETB-CSLAHNPs. Blank CSLAHNPs were prepared by two-step method using bovine serum albumin and lipid mixture composed of 60:30:10 molar ratio of dipalmitoyl-phosphatidylcholine (DPPC), cholesterol, and 1,2-distearoyl-sn-glycero-3- phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) respectively. ETB was loaded into CSLAHNPs by incubation method. Murine anti-EGFR monoclonal antibody (mAb) was reduced to hAb using tris(2-carboxyethyl)phosphine and conjugated to maleimide terminated ETB- CSLAHNPs via maleimide-thiol conjugation reaction. CSLAHNPs were further characterized for physicochemical properties including mean size, polydispersity index, zeta potential, drug loading efficiency, in vitro drug release, and in vitro serum stability. The optimized ETB- CSLAHNPs and hAb-ETB-CSLAHNPs were evaluated for their in vitro biological properties including cellular association cellular uptake, endolysosomal trafficking, cell viability, colony formation assay and western blots in two human lung adenocarcinoma cells; A549 ( having wild-type EGFR) and HCC827 (having an acquired mutation in EGFR) cells. The mean size of hAb-ETB-CSLAHNPs (targeted) and ETB-CSLAHNPs (untargeted) was between 190-210 nm, suitable for intravenous delivery. The zeta potential, drug loading, and drug entrapment efficiency were about -13 mV, 2 % w/w, and 31% w/w respectively. CSLAHNPs exhibited sustained drug release profiles over 72- 96 h in PBS pH 7.4. Fluorescent lipid tagged hAb-ETB- CSLAHNPs showed enhanced uptake and accumulated in the cells. Significant reduction in % cell viability was observed for targeted hAb-ETB- CSLAHNPs compared to control groups in HCC827 cells after 72 h. The analysis of IC50 demonstrated that both targeted hAb-ETB- CSLAHNPs and untargeted ETB-CSLAHNPs could be more effective than ETB alone in both EGFR- positive NSCLC cells. Short-term stability data at refrigerator condition demonstrated that the lyophilized form of CSLAHNPs containing 16-fold sucrose (lyoprotectant) significantly improved the physical and chemical stability compared to liquid dispersion for 60 days of storage. Overall, the results indicated that hAb-ETB- CSLAHNPs and ETB-CSLAHNPs would be promising ETB delivery systems for EGFR- overexpressing NSCLC. v TABLE OF CONTENTS CHAPTER 1. INTRODUCTION .....................................................................................1 Non-Small Cell Lung Cancer and Treatment Options .....................................................1 Chemotherapy and Molecularly Targeted Therapy for NSCLC .....................................1 Erlotinib and Its Mechanism of Action ............................................................................2 Drawbacks of Erlotinib Therapy ......................................................................................5 Barriers to Drug Delivery in Solid Tumors .....................................................................5 Hybrid Nanoparticles for Erlotinib Delivery to Solid Tumors ........................................7 Review of Hybrid Nanoparticles Literature .....................................................................8 Introduction ..................................................................................................................8 Core-shell type lipid/polymer hybrid nanoparticles ....................................................9 Advantages of CSLPHNPs ........................................................................................12 Methods of preparation of CSLPHNPs ......................................................................12 Two-step method. ................................................................................................. 13 Single-step method................................................................................................ 15 Drug loading and entrapment efficiency of CSLPHNPs ...........................................17 Surface modifications of CSLPHNPs ........................................................................18 Physicochemical characteristics of